Chemical Neurotransmission
Medication: Aristada (aripiprazole lauroxil) extended-release injectable
1. Explain the drug selected use and (One paragraph )
a. Diseases
b. Expected outcomes
2. Explain the concept of that drug’s half-life(One paragraph )
3. How long would it take for that drug to reach a steady state? (One paragraph )
a. Why
b. Give one example
4. How frequently should the medication be dosed based on the half-life? (One paragraph)
a. Why
b. Give one example
5. Explain the pharmacodynamic (One paragraph)
6. explain how the drug’s half-life effects reach a steady state(One paragraph)
The concept of half-life in pharmacology refers to how long it takes for the concentration of a drug present in the body's circulation system to be reduced by half due its elimination or metabolism through different pathways. For Aristada, the average terminal serum half-life is approximately 116 hours. This means it will take around 4.83 days for this drug’s concentration levels in the bloodstream first reduce by 50%.
To reach steady state concentrations with Aristada, it should be dosed once every two weeks because that length of time will equalize any fluctuations between doses. In other words if one dose lasts four weeks total then after each successive dose there will have been enough time for all previous doses to have dissipated from the patient’s body and reached a steady state before introducing a new dose.
The pharmacodynamics properties related to Aristada involve focusing on how it affects people at the biochemical level; meaning how does the drug interact with receptors in cells within tissue which affect our physiology over time? It works by blocking serotonin and dopamine receptors which helps stabilize mood swings associated with schizophrenia or bipolar disorder.
When a medication has been taken frequently enough that its concentration remains consistent over time, then reaches what\'s called "steady state". Reaching steady state allows one's body become accustomed to having a certain amount of drugs circulating in their bloodstream without experiencing extreme changes between doses based on its half-life.